Get the Stockscreener App
1.08
1.89%
0.02
After Hours:
1.10
0.02
+1.85%
Humacyte Inc stock is traded at $1.08, with a volume of 4.44M.
It is up +1.89% in the last 24 hours and down -12.20% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.06
Open:
$1.08
24h Volume:
4.44M
Relative Volume:
0.78
Market Cap:
$202.25M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.0093
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+6.93%
1M Performance:
-12.20%
6M Performance:
-52.63%
1Y Performance:
-78.14%
1-Day Range:
$1.05
$1.12
1-Week Range:
$0.91
$1.12
52-Week Range:
$0.91
$5.33
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.08 | 198.51M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte rises on Symvess sale to military treatment facility - MSN
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel - marketscreener.com
Humacyte Inc announces planned marketing authorization application for Symvess in Israël - marketscreener.com
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte plans to seek approval for vessel product in Israel - Investing.com
Humacyte plans to seek approval for vessel product in Israel By Investing.com - Investing.com UK
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - The Manila Times
Rate Hike: Is Humacyte Inc stock attractive for income investorsDollar Strength & Daily Entry Point Trade Alerts - moha.gov.vn
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Is Humacyte, Inc. (HUMAW) Stock Down Today? - Meyka
Can Humacyte Inc. Equity Warrant stock maintain growth trajectoryChart Pattern Recognition & Compound Your Gains With Quality Stocks - Bollywood Helpline
Humacyte's (HUMA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Humacyte Reports High Limb Salvage Rates and Durability of Symvess in Long-Term Study Published in JVS-CIT - Quiver Quantitative
Off-the-shelf blood vessel implant helps save injured limbs in study - Stock Titan
Humacyte announces credit facility of $77.5M with Avenue Capital - MSN
Regulatory Ruptures For A Lab-Grown Blood Vessel - The Lever
Lab-Grown Blood Vessel Maker Promotes Risky Off-Label Uses - Jacobin
Humacyte (NASDAQ:HUMA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Humacyte Inc. stock attractive for income investorsEarnings Risk Summary & Detailed Earnings Play Strategies - DonanımHaber
Can Humacyte Inc. stock surprise with earnings upsideWeekly Trade Summary & High Accuracy Investment Entry Signals - bolumsonucanavari.com
What catalysts could drive Humacyte Inc. Equity Warrant stock higher2025 Market Outlook & Real-Time Volume Trigger Notifications - DonanımHaber
Is Humacyte Inc. Equity Warrant stock a contrarian buy2025 Breakouts & Breakdowns & Safe Capital Growth Plans - DonanımHaber
Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterQuarterly Growth Report & Daily Profit Maximizing Trade Tips - ulpravda.ru
Published on: 2025-12-19 01:36:49 - Улправда
Is Humacyte Inc. Equity Warrant stock affected by interest rate hikesCEO Change & Reliable Breakout Forecasts - Улправда
Aug Chart Watch: Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterInsider Buying & Capital Efficient Trading Techniques - Улправда
Humacyte enters sales agreement with TD Securities - MSN
Humacyte's US$28m Market Cap Fall Books Insider Losses - simplywall.st
Humacyte’s Big Promise Still Faces A Rocky Road - Finimize
Humacyte Enters Sales Agreement with TD Securities - TipRanks
Humacyte may offer and sell shares of common stock of up to $60 million from time to time through TD Cowen, acting as agent - marketscreener.com
Humacyte (NASDAQ: HUMA) details $60M at the market stock offering - Stock Titan
[424B5] Humacyte, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Investment Review: Is Humacyte Inc Equity Warrant stock a contrarian buyJuly 2025 Short Interest & Expert Curated Trade Setups - moha.gov.vn
Humacyte secures up to $77.5 million credit facility with Avenue Capital - Investing.com Nigeria
Humacyte secures $77.5 million loan facility - MSN
Humacyte announces credit facility of up to $77.5 million with Avenue Capital - marketscreener.com
Humacyte Signs $77.5 Million Credit Facility - marketscreener.com
Humacyte Secures $77.5 Million Credit Facility with Avenue Venture Opportunities Fund to Support Growth and Development Initiatives - Quiver Quantitative
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital - marketscreener.com
Humacyte, Inc. Announces Credit Facility of Up to $77.5 Million with Avenue Capital - marketscreener.com
Total debt per share of Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte – NASDAQ:HUMAW - TradingView — Track All Markets
Humacyte Secures $77.5 Million Loan Facility - TipRanks
[8-K] Humacyte, Inc. Reports Material Event | HUMA SEC FilingForm 8-K - Stock Titan
Humacyte terminates revenue interest purchase agreement - marketscreener.com
Humacyte Terminates Revenue Interest Agreement - TipRanks
Humacyte (NASDAQ: HUMA) to issue 5.7M shares, pay $38M to end deal - Stock Titan
Wall Street Zen Upgrades Humacyte (NASDAQ:HUMA) to "Hold" - MarketBeat
Is Humacyte Inc a good long term investmentStraddle and Strangle Trades & Explosive Capital Growth Plans - earlytimes.in
Humacyte (HUMA): Benchmark remains bullish on stock - MSN
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):